Objective To explore the clinical value of 18F-fluorodeoxygiucose positron-emission tomography/computed tomography(18F-FDG PET-CT),enhanced CT and magnetic resonance imaging(MRI)in the differential diagnosis of benign and malignant pancreatic cystic lesions.Methods The imaging data of 80 patients with pancreatic cystic lesions who were admitted to the hospital were retrospectively analyzed between February 2021 and January 2023.The evaluation value of 18F-FDG PET-CT,enhanced CT and MRI for benign and malignant pancreatic cystic lesions was analyzed.Results In the 80 patients,there were 35 cases with malignant lesions and 45 cases with benign lesions.In enhanced CT examination,there were 6 cases with mucinous cystic tumors,2 cases with intraductal papillary mucinous tumors(misdiagnosed as benign lesions due to regular morphology and clear borders),5 cases with pseudocysts and 1 case with true cysts(misdiagnosed as malignant lesions due to unclear borders and enhanced edges).In MRI examination,there were 5 cases with mucinous cystic tumors(misdiagnosed as benign lesions),showing inconspicuous display,flaky or irregular distribution in routine plain scan,4 cases with pseudocysts and and 1 case with true cysts(misdiagnosed as malignant lesions due to unclear borders or uneven enhancement).In 18F-FDG PET-CT examination,there were 2 cases with intraductal papillary mucinous tumors[misdiagnosed as benign lesions due to standardized uptake value(SUVmax)not greater than 2.5)and 1 case with serous cystic tumor(misdiagnosed as malignant lesions due to SUVmax greater than 2.5).The accuracy and specificity rates of 18F-FDG PET-CT detection were 96.25％and 97.14％,which were significantly higher than those of enhanced CT and MRI.The sensitivity rate of 18F-FDG PET-CT detection was 95.56％,significantly higher than that of enhanced CT(P＜0.05).Conclusion Compared with CT and MRI,18F-FDG PET-CT can provide more accurate assessment for benign and malignant pancreatic cystic lesions,which provides data support for selection of treatment options and prognosis prediction.
万方数据